人 CNDP1 抗体对
01AB03049
Carnosine dipeptidase 1 (CNDP1) is a 56.8 kDa homodimeric M20 metalloprotease primarily expressed in the brain, where it functions as the principal human carnosinase. It specifically hydrolyzes Xaa-His dipeptides, exhibiting its highest catalytic activity toward carnosine and anserine using Zn2+ as a cofactor. The enzyme exists in both intracellular and secreted forms, contributing to protein hydrolysis, tissue regeneration, and cell cycle regulation. Structurally, CNDP1 contains a signal peptide and a characteristic beta-strand arrangement. Clinically, mutations in the CNDP1 gene are linked to rare metabolic disorders such as homocarnosinosis and carnosinemia, which are characterized by the accumulation of carnosine and associated neurological symptoms. Additionally, its downregulation has been identified as a poor prognostic indicator in hepatocellular carcinoma and other cancers, suggesting its utility as a potential biomarker for disease progression.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- CNDP1
- 基因别名
- CN1; CPGL2
- 蛋白别名
- carnosine dipeptidase 1; CNDP1
- UniProt
- Q96KN2
- 物种
- Human
产品详情
- 靶点名称
- CNDP1
- 蛋白名称
- carnosine dipeptidase 1
- 蛋白别名
- Beta-Ala-His dipeptidase; CNDP dipeptidase 1; Carnosine dipeptidase 1; Glutamate carboxypeptidase-like protein 2; Serum carnosinase
- 靶点基因名
- CNDP1
- 基因别名
- CN1; CPGL2
- UniProt
- Q96KN2
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Carnosine dipeptidase 1 (CNDP1) is a 56.8 kDa homodimeric M20 metalloprotease primarily expressed in the brain, where it functions as the principal human carnosinase. It specifically hydrolyzes Xaa-His dipeptides, exhibiting its highest catalytic activity toward carnosine and anserine using Zn2+ as a cofactor. The enzyme exists in both intracellular and secreted forms, contributing to protein hydrolysis, tissue regeneration, and cell cycle regulation. Structurally, CNDP1 contains a signal peptide and a characteristic beta-strand arrangement. Clinically, mutations in the CNDP1 gene are linked to rare metabolic disorders such as homocarnosinosis and carnosinemia, which are characterized by the accumulation of carnosine and associated neurological symptoms. Additionally, its downregulation has been identified as a poor prognostic indicator in hepatocellular carcinoma and other cancers, suggesting its utility as a potential biomarker for disease progression.